Daridorexant:A Novel Dual Orexin Receptor Antagonist for Clinical Advantages of Treating Adult Insomnia
Daridorexant is a novel dual orexin receptor antagonist(DORA)for the treatment of chronic insomnia disorder in adults.Daridorexant demonstrates a unique set of clinical advantages over traditional benzodiazepine and non-benzodiazepine sleep aids.Daridorexant can significantly improve sleep latency,prolong total sleep duration,reduce nocturnal awakenings and maintain normal sleep band structure.At the same time,it is safe,has low risk of drug dependence and abuse,and does not cause rebound insomnia.In addition,daridorexant significantly improves daytime functioning,including alertness,attention and memory.Daridorexant has been approved in the European Union for the treatment of chronic insomnia in adults,and is the first DORA drug to be approved also for improving daytime function.It has also been approved by the U.S.FDA for the treatment of insomnia in adults.Based on the data from non-clinical and clinical studies of daridorexant,this article comprehensively reviews its unique pharmacological effects and clinical advantages as a novel treatment for adult insomnia,and provides a reference for its application in the field of insomnia treatment.
万方数据
维普
